About Max
This author has not written his bio yet.
But we are proud to say that Max contributed 566 entries already.
Entries by Max
Newsletter 20/2025
/in Newsletter/by MaxLAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Hi fellow warriors! New week of news. This time we also have some very positive updates about the CRISPR gene editing method. Although it doesn’t directly relate to prostate cancer, it’s something very important. Stay strong and fight on! As usual, we […]
Project Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 225Ac abiraterone abiraterone acetate ADC ADT AI ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA cancer immunotherapy CAR-T clinical trial crispr darolutamide docetaxel drug repurposing drug resistance enzalutamide HRR immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data T-cell therapy theranostics
Latest Posts
- SPR1020: a Promising PARP1-Selective Inhibitor in Advanced Solid Tumors (Including mCRPC) February 6, 2026
- Dual-Action Nanomaterial Eradicates Cancer Cells And Spares Healthy Tissue February 6, 2026
- Phase 1 Trial GTB-5550, a Immunotherapy Targeting B7-H3 in Solid Tumors (Including mCRPC) February 6, 2026
- WOLVERINE Study Shows The Benefits of Metastases Directed Therapy February 6, 2026
